Entinostat is a novel oral class I selective HDAC inhibitor that has been shown to inhibit breast cancer tumorgrowth, angiogenesis, and metastasis (Srivastava, Kurzrock, & Shankar, 2010). This evidence concerns the gene HDAC9 and breast cancer.